[Articles] Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospective cohort study This nomogram predicts ADT-free survival after MDT in oligorecurrent prostate cancer. While individual-level discrimination was modest, risk-group stratification showed meaningful separation, supporting its potential use in treatment selection. The Lancet Oncology March 2, 2026 Original source
[Articles] Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial Adding ipilimumab and nivolumab to percutaneous hepatic perfusion significantly improved progression-free survival, but with a higher rate of adverse events. The combination therapy offers a promising new treatment paradigm for patients with metastatic uveal melanoma. These results would ideally be validated in larger, multicentre randomised trials; however, conducting such studies is challenging due to the low incidence of uveal melanoma. The Lancet Oncology March 2, 2026 Original source
[Articles] Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data Cancer-related NHS hospital care costs by stage at diagnosis differed between cancer types; this heterogeneous pattern could inform detailed and nuanced economic evaluations of early detection initiatives. The Lancet Oncology March 2, 2026 Original source
[Articles] MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study MRI-guided optimisation of neoadjuvant chemotherapy duration was associated with favourable 3-year event-free survival outcomes in patients with stage II–III HER2-positive breast cancer. This approach represents a novel strategy that reduces treatment burden, minimises toxicity, and preserves quality of life in a subset of patients with early HER2-positive breast cancer. The Lancet Oncology March 2, 2026 Original source
[Articles] Assessing the global demand and supply of brachytherapy resources: a population-based observational study Global access to brachytherapy remains profoundly unequal, with adequate coverage largely limited to HICs. Resource gaps are greatest in lower-income settings, where patients also travel farthest. Investment in new centres is urgently needed to reduce geographical and economic barriers to access. The Lancet Oncology March 2, 2026 Original source
[Articles] Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study Vibostolimab coformulated with pembrolizumab did not provide additional clinical benefit versus pembrolizumab as adjuvant therapy in participants with resected stage IIB–IV melanoma. Pembrolizumab monotherapy remains a standard of care for resected high-risk melanoma. The Lancet Oncology March 2, 2026 Original source
[Articles] Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 The stable incidence and declining mortality rates of female breast cancer in high-income nations reflect success in screening, diagnosis, and treatment. In contrast, the concurrent rise in incidence and mortality in other regions signals health system deficits. Without effective interventions, many countries will fall short of the WHO Global Breast Cancer Initiative's ambitious target of achieving an annual reduction of… The Lancet Oncology March 2, 2026 Original source
[Articles] Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial This 10-year follow-up confirms the non-inferiority of the ultra-hypofractionated radiotherapy regimen compared with the conventionally fractionated, with similar toxicity profiles. The findings support the seven-fraction schedule as a safe, effective, and practical standard-of-care option for patients with intermediate-risk prostate cancer. The Lancet Oncology March 2, 2026 Original source
[Perspectives] Seismic vulnerability of Türkiye's radiotherapy centres: a nationwide analysis Earthquakes constitute major natural hazards, with the potential to cause extensive damage to infrastructure, substantial loss of life, and economic consequences. Türkiye is situated at the intersection of the Arabian and Eurasian tectonic plates and is traversed by both the North Anatolian and East Anatolian fault lines, resulting in high seismic activity across the region. In the last century, the… The Lancet Oncology March 2, 2026 Original source
[Perspectives] The legacy of science and innovation pioneers Marie and Pierre Curie: Musée Curie The Musée Curie, nestled in the historic heart of Paris near the Panthéon, offers a compelling journey through the extraordinary legacy of Marie and Pierre Curie—pioneers whose groundbreaking work in radioactivity transformed both science and medicine. As a dedicated centre for preserving and showcasing their contributions, the museum provides invaluable insights into the origins of radiological research and its profound… The Lancet Oncology March 2, 2026 Original source
[News] FDA fast-tracks first inhalable gene therapy for lung cancer The US Food and Drug Administration (FDA) has fast-tracked a promising new gene therapy, KB707, which is inhaled as a fine mist for the targeted treatment of advanced or metastatic non-small-cell lung cancer. The Lancet Oncology March 2, 2026 Original source
[News] France plans national targeted lung cancer screening On Feb 4, 2026, Health Minister Stéphanie Rist announced that the French Government will launch a targeted lung cancer screening trial in March, 2026, with the aim of making screening systematic by 2030. The Lancet Oncology March 2, 2026 Original source
[News] US EPA turning a blind eye to formaldehyde's cancer risks, critics contend A coalition of 13 Democratic state attorney generals is urging the Trump administration to drop a “dangerous and scientifically unsupported” revision to a federal formaldehyde-inhalation risk assessment they say would put workers, consumers, and communities at risk of formaldehyde-linked cancers and asthma. The Lancet Oncology March 2, 2026 Original source
[News] Clinicians warn plan to hit NHS cancer targets within 3 years needs more detail The UK National Health Service (NHS) will meet all three core cancer standards by 2029, according to a new National Cancer Plan for England, published on Feb 4, 2026. This is despite national treatment targets having not been hit for more than a decade. The Lancet Oncology March 2, 2026 Original source
[News] Unauthorised cancer drug in Zimbabwe raises patient safety concerns On Jan 27, 2026, Zimbabwe's Medicines Control Authority (MCAZ) alerted citizens about the circulation of an unauthorised formulation of goserelin acetate, a hormone therapy used in the treatment of prostate and breast cancer. It warned that the product could pose risks to patient safety. “Our records show that this product was not formally imported into Zimbabwe. The MCAZ cannot therefore… The Lancet Oncology March 2, 2026 Original source
[News] New free trade agreement might bring cheaper cancer drugs to India On Jan 27, 2026, India and the EU announced the conclusion of a comprehensive free trade agreement (FTA) as part of the 16th EU–India Summit, held in New Delhi, India. The new agreement creates a free trade zone affecting more than 2 billion people by eliminating or reducing tariffs on chemical inputs, medical devices, and pharmaceuticals, including cancer drugs. The Lancet Oncology March 2, 2026 Original source
[News] Lithuania introduces taxes on sugar-sweetened beverages Lithuania has now joined a growing list of more than 100 countries worldwide that have introduced a tax on sugar-sweetened beverages (SSBs). The tax, introduced from Jan 1, 2026, means the Baltic nation is one of many countries using fiscal policies to help encourage healthier diets across its population. Lithuania will also be taxing artificially sweetened beverages. The Lancet Oncology March 2, 2026 Original source
[News] NHS England sets up world's first national genetic cancer risk register The National Health Service (NHS) in England, UK, has set up the world's first national genetic cancer risk register to help track and screen individuals at higher risk of developing cancer and offer preventive and personalised care. The Lancet Oncology March 2, 2026 Original source
[Correspondence] Standardising MET amplification testing: limitations of the GCN ≥6 criterion – Authors' reply We thank Yuxin Liu and colleagues for their interest in the KUNPENG study and concur that a clinically meaningful MET amplification cutoff is crucial to trial design and interpretation.1 Indeed, our selection of a gene copy number (GCN) of six or higher assessed by fluorescence in-situ hybridisation (FISH) was grounded in a biological rationale and clinical precedent. Mechanistically, MET amplification… The Lancet Oncology March 2, 2026 Original source
[Correspondence] Standardising MET amplification testing: limitations of the GCN ≥6 criterion We read with great interest the phase 2 KUNPENG trial by Yi-Long Wu and colleagues.1 The reported objective response rate of 48·8% with vebreltinib in MET amplification-driven non-small-cell lung cancer is promising. However, the use of a gene copy number (GCN) of six or higher as the sole enrolment criterion obscures crucial biological heterogeneity within this population. This methodological choice… The Lancet Oncology March 2, 2026 Original source